antibody

RUNX1 Polyclonal Antibody

MBS126543

0.05 mL

230 USD

polyclonal

rabbit

nonconjugated

human, mouse, rat

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation

Antibody

RUNX1 Polyclonal Antibody

RUNX1

AML1; AML1-EVI-1; AMLCR1; CBFA2; EVI-1; PEBP2Ab

Runt-related transcription factor 1; Runt-related transcription factor 1; runt-related transcription factor 1; CBF-alpha-2; PEA2-alpha B; PEBP2-alpha B; oncogene AML-1; AML1-EVI-1 fusion protein; acute myeloid leukemia 1 protein; SL3-3 enhancer factor 1 alpha B subunit; SL3/AKV core-binding factor alpha B subunit; core-binding factor, runt domain, alpha subunit 2; polyomavirus enhancer-binding protein 2 alpha B subunit; runt-related transcription factor 1; Acute myeloid leukemia 1 protein; Core-binding factor subunit alpha-2; CBF-alpha-2; Oncogene AML-1; Polyomavirus enhancer-binding protein 2 alpha B subunit; PEA2-alpha B; PEBP2-alpha B; SL3-3 enhancer factor 1 alpha B subunit; SL3/AKV core-binding factor alpha B subunit

RUNX1

RUNX1; RUNX1; AML1; CBFA2; EVI-1; AMLCR1; PEBP2aB; AML1-EVI-1; AML1; CBFA2; CBF-alpha-2; PEA2-alpha B; PEBP2-alpha B

RUNX1_HUMAN

Polyclonal

IgG

Rabbit

Human, Mouse, Rat

453

Affinity Purification

1mg/ml

Store at -20 degree C (regular) or -80 degree C (long term). Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Western Blot (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorecence (IF), Immunoprecipitation (IP)

WB: 1:500 - 1:2000. IHC: 1:50 - 1:200. ICC: 1:50 - 1:200. IF: 1:50 - 1:200. IP: 1:20 - 1:100

Species: Human. Route: Synthetic Peptide

Immunogen: A synthetic peptide of human RUNX1. Calculated Molecular Weight: 51kDa

Polyclonal

AML1 (also known as Runx1, CBFA2, and PEBP2alphaB) is a member of the core binding factor (CBF) family of transcription factors (1,2). It is required for normal development of all hematopoietic lineages (3-5). AML1 forms a heterodimeric DNA binding complex with its partner protein CBFbeta and regulates the expression of cellular genes by binding to promoter and enhancer elements. AML1 is commonly translocated in hematopoietic cancers: chromosomal translocations include t(8;21) AML1-ETO, t(12;21) TEL-AML, and t(8;21) AML-M2 (6). Phosphorylation of AML1 on several potential serine and threonine sites, including Ser249, is thought to occur in an Erk-dependent manner (7,8).

215274205

Q01196.3

Q01196

453

Acute Myeloid Leukemia Pathway (83117); Acute Myeloid Leukemia Pathway (529); Chronic Myeloid Leukemia Pathway (83116); Chronic Myeloid Leukemia Pathway (528); Pathways In Cancer (83105); Transcriptional Misregulation In Cancer Pathway (523016); Transcriptional Misregulation In Cancer Pathway (522987)

Core binding factor (CBF) is a heterodimeric transcription factor that binds to the core element of many enhancers and promoters. The protein encoded by this gene represents the alpha subunit of CBF and is thought to be involved in the development of normal hematopoiesis. Chromosomal translocations involving this gene are well-documented and have been associated with several types of leukemia. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

AML1: CBF binds to the core site, 5 -PYGPYGGT-3 , of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B- dependent transcriptional activation. Heterodimer with CBFB. RUNX1 binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Isoform AML-1L can neither bind DNA nor heterodimerize. Interacts with TLE1 and ALYREF/THOC4. Interacts with ELF1, ELF2 and SPI1. Interacts via its Runt domain with the ELF4 N-terminal region. Interaction with ELF2 isoform 2 (NERF-1a) may act to repress RUNX1-mediated transactivation. Interacts with KAT6A and KAT6B. Interacts with SUV39H1, leading to abrogation of transactivating and DNA-binding properties of RUNX1. Interacts with YAP1. Interacts with HIPK2. Interaction with CDK6 prevents myeloid differentiation, reducing its transcription transactivation activity. Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood. 11 isoforms of the human protein are produced by alternative splicing. Protein type: Oncoprotein; Transcription factor; DNA-binding. Chromosomal Location of Human Ortholog: 21q22.3. Cellular Component: nucleoplasm; intracellular membrane-bound organelle; cytoplasm; basement membrane; nucleus. Molecular Function: protein binding; protein homodimerization activity; DNA binding; protein heterodimerization activity; calcium ion binding; transcription factor binding; transcription factor activity; ATP binding. Biological Process: hair follicle morphogenesis; central nervous system development; transcription, DNA-dependent; embryonic hemopoiesis; in utero embryonic development; positive regulation of transcription, DNA-dependent; positive regulation of granulocyte differentiation; regulation of signal transduction; liver development; negative regulation of granulocyte differentiation; peripheral nervous system neuron development; behavioral response to pain; positive regulation of angiogenesis; myeloid progenitor cell differentiation; positive regulation of interleukin-2 production; myeloid cell differentiation; positive regulation of transcription from RNA polymerase II promoter; hemopoiesis; skeletal development. Disease: Platelet Disorder, Familial, With Associated Myeloid Malignancy; Leukemia, Acute Myeloid; Rheumatoid Arthritis

0.05 mL

230 USD

0.1 mL

305

0.2 mL

460